Long-Term Follow-up of Subjects Who Were Treated With ST-920
Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
1 other identifier
observational
48
5 countries
13
Brief Summary
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2021
Longer than P75 for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 16, 2021
CompletedFirst Submitted
Initial submission to the registry
August 20, 2021
CompletedFirst Posted
Study publicly available on registry
September 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2039
May 25, 2025
May 1, 2025
7.5 years
August 20, 2021
May 21, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate long-term safety of ST-920
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
4 years
Study Arms (1)
Subjects who received ST-920
Subjects who received ST-920 in a separate parent trial
Interventions
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Eligibility Criteria
All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.
You may qualify if:
- Subjects who received ST-920 therapy in a separate parent trial
- Subjects who have consented to participate in this LTFU study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
University of California, Irvine
Irvine, California, 92697, United States
University of South Florida
Tampa, Florida, 33620, United States
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, 55455, United States
Mt. Sinai Hospital
New York, New York, 10029, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia, 22030, United States
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, T2E 7Z4, Canada
University Hospital of Würzburg
Würzburg, Germany
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
Royal Free Hospital
London, United Kingdom
Biospecimen
plasma, serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Sangamo Therapeutics, Inc.
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 20, 2021
First Posted
September 10, 2021
Study Start
August 16, 2021
Primary Completion (Estimated)
March 1, 2029
Study Completion (Estimated)
March 1, 2039
Last Updated
May 25, 2025
Record last verified: 2025-05